Lucid Diagnostics (LUCD) Stock Analysis

What Lucid Diagnostics does

Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

Key metrics

ETFs linked to LUCD

Broad-market and Healthcare sector ETFs an investor holding Lucid Diagnostics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LUCD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Lucid Diagnostics?

Lucid Diagnostics trades under the ticker LUCD on NASDAQ.

Which exchange is LUCD listed on?

LUCD is listed on NASDAQ.

What sector does Lucid Diagnostics operate in?

Lucid Diagnostics is classified in the Healthcare sector (Medical - Devices industry).

How can PortView help analyze LUCD in a portfolio?

PortView shows LUCD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.